Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAP4K3 | Q8IVH8 | 12/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038434 | 0.86 | EGFR (0.57) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4035619 | 0.86 | EGFR (0.55) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4052605 | 0.84 | EGFR (0.55) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4044869 | 0.84 | MAP4K3 (0.56) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4052067 | 0.83 | EGFR (0.55) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4038747 | 0.83 | EGFR (0.54) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4048973 | 0.83 | EGFR (0.50) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4045036 | 0.83 | EGFR (0.57) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4036451 | 0.80 | EGFR (0.62) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL3952099 | 0.80 | EGFR (0.59) | EGFRMAP4K3FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |